Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | FPR3 | P25089 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | SDCBP | O00560 | 1/20 | 0.45 |
| ▸ | SDC2 | P34741 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3180689 | 0.91 | L3MBTL1 (0.61) | L3MBTL1GAANAMPTCA1CA2 | |
| SCHEMBL27840005 | 0.87 | KDM4A (0.46) | L3MBTL1GAANAMPTCA1CA2 | |
| SCHEMBL81094 | 0.87 | FPR3 (0.58) | L3MBTL1GAANAMPTCA1CA2 | |
| SCHEMBL506202 | 0.85 | GAA (0.57) | L3MBTL1GAANAMPTCA1CA2 | |
| SCHEMBL12685839 | 0.85 | L3MBTL1 (0.56) | L3MBTL1GAANAMPTCA1CA2 | |
| SCHEMBL1164796 | 0.85 | L3MBTL1 (0.56) | L3MBTL1GAANAMPTCA1CA2 | |
| SCHEMBL5796279 | 0.85 | L3MBTL1 (0.56) | L3MBTL1GAANAMPTCA1CA2 | |
| SCHEMBL15259134 | 0.85 | L3MBTL1 (0.56) | L3MBTL1GAANAMPTCA1CA2 | |
| SCHEMBL8372079 | 0.85 | L3MBTL1 (0.56) | L3MBTL1GAANAMPTCA1CA2 | |
| SCHEMBL851272 | 0.84 | GLS (0.55) | L3MBTL1NAMPTCA1HDAC1KDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583861-B2 | Derivatives of imidazo[4,5-d]pyridazine, their preparation and their therapeutic application | SANOFI (FR) | 2026-03-24 | — | — | US | disclosed |
| EP-4288438-B1 | DERIVATIVES OF IMIDAZO[4,5-D]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2026-02-18 | — | — | EP | disclosed |
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12528785-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | MERCK SHARP & DOHME LLC (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4608456-A1 | COMPOUNDS FOR DETECTION OF ORAL INFLAMMATION | Julius-Maximilians-Universität Würzburg (DE) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025085489-A1 | GSPT1-DEGRADING COMPOUNDS, ANTI-CD33 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025085416-A1 | GSPT1 COMPOUNDS AND METHODS OF USE OF THE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-04-03 | — | — | US | disclosed |
| US-20050014833-A1 | Cyclic compound and ppar agonist | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1452521-A1 | CYCLIC COMPOUND AND PPAR AGONIST | Eisai Co., Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
| US-6680311-B1 | ANTICARCINOGENIC, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | ELI LILLY AND COMPANY | 2004-01-20 | — | — | US | disclosed |
| US-6384061-B1 | HYDANTOIN COMPOUNDS REPRESENTED BY FORMULA (I) WHICH SHOWS AN INHIBITORY ACTIVITY AGAINST FARNESYL TRANSFERASE, AND THUS CAN BE USED AS AN ANTI-CANCER AGENT, OR PHARMACEUTICALLY ACCEPTABLE SALTS | LG CHEMICAL LTD. (KR) | 2002-05-07 | — | — | US | disclosed |
| EP-0934065-A4 | PHARMACEUTICAL COMPOUNDS | LILLY CO ELI (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-1000036-A1 | HYDANTOIN DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE | LG CHEMICAL LIMITED (KR) | 2000-05-17 | — | — | EP | disclosed |
| CN-1233957-A | Pharmaceutical compositions | LILLY CO ELI (US) | 1999-11-03 | — | — | CN | disclosed |
| EP-0934065-A1 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1999005117-A1 | HYDANTOIN DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE | LG CHEMICAL LTD. (KR) | 1999-02-04 | — | — | WO | disclosed |
| WO-1998008505-A1 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583861-B2 | Derivatives of imidazo[4,5-d]pyridazine, their preparation and their therapeutic application | TLR7, TLR8, TLR6 | L3MBTL1 4094/4885GAA 3276/4885NAMPT 3682/4885 |
| US-20050014833-A1 | Cyclic compound and ppar agonist | PPARA, PPARG, PPARD | L3MBTL1 2870/4885GAA 4863/4885NAMPT 1200/4885 |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | L3MBTL1 831/4885GAA 1806/4885NAMPT 1789/4885 |
| US-12528785-B2 | MDM2 degraders and uses thereof | MDM2, ADRM1, RBX1 | L3MBTL1 239/4885GAA 2635/4885NAMPT 4861/4885 |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | L3MBTL1 2712/4885GAA 2022/4885NAMPT 3968/4885 |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | IL4I1, IL4, IL2 | L3MBTL1 4116/4885GAA 1407/4885NAMPT 1522/4885 |
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | RICTOR, MTOR, MLST8 | L3MBTL1 419/4885GAA 4223/4885NAMPT 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.